Vistagen Therapeutics (VTGN) Stock: Buy, Sell, or Hold?
VTGN - Vistagen Therapeutics, Inc. Common Stock
$0.28
0.00 (-0.57%)
▼
5d:
+2.93%
30d:
+14.23%
90d:
+14.32%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When VTGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
ℹ️ NEUTRAL: VTGN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
ℹ️ NEUTRAL: VTGN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VTGN is currently trading at $0.28, which is considered slightly high relative to its 30-day fair value range of $0.23 to $0.29.
Technical Outlook: Technically, VTGN is in a strong downtrend. Immediate support is located at $0.23, while resistance sits at $0.55.
Market Sentiment: VTGN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.00 (+255.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VTGN is in a strong downtrend. Immediate support is located at $0.23, while resistance sits at $0.55.
Market Sentiment: VTGN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.00 (+255.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.23 -
$0.29
Company Quality Score
31/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (15/100)
- BULLISH: Trading 255.9% below Wall St target ($1.00)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.23 -
$0.29
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.23
Resistance Level
$0.55
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.29
Wall Street Target
$1.00
(+255.9%)
Revenue Growth (YoY)
504.9%
Share & Embed Analysis
Last updated: October 03, 2026 2:42 PM ET
Data refreshes hourly during market hours. Next update: 3:42 PM
Data refreshes hourly during market hours. Next update: 3:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VTGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
